Skip to content
value.today

Pelthos Therapeutics Inc.

🇺🇸 Durham, North Carolina, USAPharmaceuticalsFounded 2021

Formerly Channel Therapeutics Corporation, Chromocell Therapeutics Corporation

Pelthos Therapeutics Inc. is listed today as Pelthos Therapeutics Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Pelthos Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2026$58 MPrivate placement after listing$50 to $250 million

Pelthos Therapeutics Inc.: Private sale, Oct 2026

Investors in this round

7 investors had bought by the notice of Nov 16, 2026: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Pelthos Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$58 M of $58 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • John M. Gay · Executive Officer · Chief Financial Officer, Treasurer and Secretary
  • Peter Greenleaf · Executive Officer, Director · Chairman
  • Sai Rangarao · Executive Officer · Chief Commercial Officer
  • Scott Plesha · Executive Officer, Director · Chief Executive Officer
  • Andrew Einhorn · Director
  • Ezra Friedberg · Director
  • Matthew Pauls · Director
  • Richard Baxter · Director
  • Richard Malamut · Director
  • Todd Davis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John M. Gay, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Nov 16, 2026. Read the notice at the SEC.

equity, optionsSEC
Nov 2025$18 MPrivate placement after listing$10 to $50 million

Pelthos Therapeutics Inc.: Private sale, Nov 2025

Investors in this round

8 investors had bought by the notice of Nov 19, 2025: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Pelthos Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them, other: Senior secured convertible notes, which are convertible into shares of the Company's common stock, par value $0.0001 per share.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Francis Knuettel II · Executive Officer · Chief Financial Officer
  • Sai Rangarao · Executive Officer · Chief Commercial Officer
  • Scott Plesha · Executive Officer, Director · Chief Executive Officer
  • Ezra Friedberg · Director
  • Matthew Pauls · Director
  • Peter Greenleaf · Director
  • Richard Baxter · Director
  • Richard Malamut · Director
  • Todd Davis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Francis Knuettel II, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Nov 19, 2025. Read the notice at the SEC.

optionsSEC
Jul 2025$50 MPrivate placement after listing$50 to $250 million

Pelthos Therapeutics Inc.: Private sale, Jul 2025

Investors in this round

13 investors had bought by the notice of Jul 10, 2025: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Pelthos Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Series A Convertible Preferred Stock, par value $0.0001 per share, convertible into shares of the Company's common stock, par value $0.0001 per share.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Francis Knuettel II · Executive Officer · Chief Financial Officer, Treasurer and Secretary
  • Sai Rangarao · Executive Officer · Chief Commercial Officer
  • Scott Plesha · Executive Officer, Director · Chief Executive Officer and President
  • Ezra Friedberg · Director
  • Matthew Pauls · Director
  • Peter Greenleaf · Director
  • Richard Baxter · Director
  • Richard Malamut · Director
  • Todd Davis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Represents a purchase price consisting of (i) the conversion of approximately $0.1M payable under an outstanding convertible note issued by the Company and (ii) an aggregate of $33,815,252 in shares of Series A Preferred Stock and Common Stock.”

Signed by Francis Knuettel II, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Jul 10, 2025. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Pelthos Therapeutics Inc., its revenue in fiscal 2025 came from these product and service lines: Net product revenues $16.21 million (96%), License and collaboration revenues $590,000 (4%).

    Annual report (SEC XBRL) · Dec 2025

  • Pelthos Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2026).

    SEC Form D · Nov 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2026

Products and services#

No products or services of Pelthos Therapeutics Inc. are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Pelthos Therapeutics Inc.
InvestorKindAmountRoundRoleSource
Ligand Pharmaceuticals IncCompanynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2025)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Pelthos Therapeutics Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pelthos Therapeutics Inc.
NameRoleNamed in
John M. GayChief Financial Officer, Treasurer and SecretaryNov 2026
Peter GreenleafChairmanNov 2026
Sai RangaraoChief Commercial OfficerNov 2026
Scott PleshaChief Executive OfficerNov 2026
Francis Knuettel IIChief Financial OfficerNov 2025
Andrew EinhornDirectorNov 2026
Ezra FriedbergDirectorNov 2026
Matthew PaulsDirectorNov 2026
Peter GreenleafChairmanNov 2026
Richard BaxterDirectorNov 2026
Richard MalamutDirectorNov 2026
Scott PleshaChief Executive OfficerNov 2026
Todd DavisDirectorNov 2026

Went public since 2023. Its SEC number is that of a company listed on a stock exchange.